PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1999 July; 80(9): 1306–1311.
PMCID: PMC2363085

Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women

Abstract

Hybrid Capture II (HC-II) is a commercial human papillomavirus (HPV) detection test designed to detect 18 HPV types divided into high-risk and low-risk groups. We have tested 1647 scrapes from 1518 unselected women attending routine cytological screening by this assay for the detection of histologically proven high-grade lesions. The reliability of this test was also evaluated on 117 fresh cone biopsy samples. HPV DNA has been detected in 400 scrapes (24.3%), 296 containing a high-risk HPV (18.0%). All the smears evocative of high-grade lesions were positive for high-risk HPV, and high-risk HPV were detected in all the 34 cases presenting a histologically proven high-grade lesion and in 68 (97.1%) of the 70 cone biopsy samples showing a high-grade lesion or an invasive carcinoma. Thus, the sensitivity was superior to the sensitivity of cytology (85.3%). Nevertheless, the quantitative approach provided by the HC-II assay for the assessment of the viral load could not clearly distinguish among cases with or without high-grade lesions. Thus this assay is recommended for the screening of high-grade lesions on a large scale, in association with classic cytology. © 1999 Cancer Research Campaign

Keywords: human papillomavirus, cervical cancer, cytological screening

Full Text

The Full Text of this article is available as a PDF (78K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995 Jun 7;87(11):796–802. [PubMed]
  • Clavel C, Bory JP, Rihet S, Masure M, Duval-Binninger I, Putaud I, Lorenzato M, Quereux C, Birembaut P. Comparative analysis of human papillomavirus detection by hybrid capture assay and routine cytologic screening to detect high-grade cervical lesions. Int J Cancer. 1998 Feb 9;75(4):525–528. [PubMed]
  • Clavel C, Masure M, Putaud I, Thomas K, Bory JP, Gabriel R, Quereux C, Birembaut P. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol. 1998 Oct;51(10):737–740. [PMC free article] [PubMed]
  • Diagnostic and therapeutic technology assessment. Human papillomavirus DNA testing in the management of cervical neoplasia. JAMA. 1993 Dec 22;270(24):2975–2981. [PubMed]
  • Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995 Mar;172(3):946–954. [PubMed]
  • Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 1994 Jan;69(1):167–171. [PMC free article] [PubMed]
  • Farthing A, Masterson P, Mason WP, Vousden KH. Human papillomavirus detection by hybrid capture and its possible clinical use. J Clin Pathol. 1994 Jul;47(7):649–652. [PMC free article] [PubMed]
  • Gaarenstroom KN, Melkert P, Walboomers JMM, Van Den Brule AJC, Van Bommel PFJ, Meyer CJLM, Voorhorst FJ, Kenemans P, Helmerhorst ThJM. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994 Mar;4(2):73–78. [PubMed]
  • Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol. 1995 Apr;172(4 Pt 1):1150–1157. [PubMed]
  • Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995 Sep 20;87(18):1365–1371. [PubMed]
  • Kaufman RH, Adam E, Icenogle J, Lawson H, Lee N, Reeves KO, Irwin J, Simon T, Press M, Uhler R, et al. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):87–92. [PubMed]
  • Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992 Oct 29;327(18):1272–1278. [PubMed]
  • Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992 Mar;79(3):328–337. [PubMed]
  • Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995 May 4;61(3):306–311. [PubMed]
  • Richart RM, Wright TC., Jr Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer. 1993 Feb 15;71(4 Suppl):1413–1421. [PubMed]
  • Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, van Ballegooijen M, Meijer CJ. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996 Dec 11;68(6):766–769. [PubMed]
  • Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lewis R, Kuypers J, Manos MM, Scott DR, Sherman ME, et al. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol. 1995 Mar;33(3):545–550. [PMC free article] [PubMed]
  • Sun XW, Ferenczy A, Johnson D, Koulos JP, Lungu O, Richart RM, Wright TC., Jr Evaluation of the Hybrid Capture human papillomavirus deoxyribonucleic acid detection test. Am J Obstet Gynecol. 1995 Nov;173(5):1432–1437. [PubMed]
  • Van Den Brule AJ, Walboomers JM, Du Maine M, Kenemans P, Meijer CJ. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer. 1991 May 30;48(3):404–408. [PubMed]
  • Wright TC, Jr, Lorincz A, Ferris DG, Richart RM, Ferenczy A, Mielzynska I, Borgatta L. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol. 1998 May;178(5):962–966. [PubMed]
  • zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131–156. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK